HCA Healthcare vs Tenet Healthcare
HCA and THC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCA and THC compare
HCA Healthcare is the larger company, worth 4.5 times as much as Tenet Healthcare ($106B against $23.3B).
On earnings, Tenet Healthcare is cheaper: it trades at 8.5× trailing earnings, against 16.8× for HCA Healthcare.
Tenet Healthcare grew revenue faster over the last twelve months (6.2% versus 5.8% for HCA Healthcare).
HCA Healthcare pays a dividend yielding 0.60%; Tenet Healthcare does not pay one.
Tenet Healthcare scores higher on the StockData Score (13 against 9 for HCA Healthcare), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCA | THC |
|---|---|---|
| Size and price | ||
| Market cap | $106B | $23.3B |
| Share price | $506.04 | $292.97 |
| Change, 1 year | 10.2% | 50.5% |
| Change, 5 years | 112% | 278% |
| Beta (5Y) | 0.73 | 1.14 |
| Employees | 320K | 100K |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 1 | 4 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 16.8× | 8.5× (better) |
| P/S | 1.3× | 1.1× (better) |
| P/B | – | 4.3× |
| EV/EBITDA | 10.0× | 5.7× (better) |
| P/FCF | 17.7× | 7.0× (better) |
| PEG | 1.20 | 0.14 (better) |
| FCF yield | 5.7% | 14.3% (better) |
| Fair value | $495.17 | $458.44 |
| Margin of safety | −2.2% | 36.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.8% | 6.2% (better) |
| Revenue growth, 5Y average | 8.0% (better) | 3.9% |
| Net income growth (TTM) | 6.8% | – |
| EPS growth (TTM) | 16.7% | 136% (better) |
| EPS growth, 5Y average | 21.0% | 32.8% (better) |
| Profitability | ||
| Operating margin | – | 24.4% |
| Net margin | 8.6% | – |
| FCF margin | 7.6% | 15.0% (better) |
| Return on invested capital | – | 28.2% |
| Financial health | ||
| Debt / equity | – | 2.43 |
| Net debt / EBITDA | 3.11 | 1.68 (better) |
| Interest coverage | – | 6.6× |
| Current ratio | 0.82 | 1.58 (better) |
| Altman Z-score | 1.93 | 2.33 (better) |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Dividend yield | 0.60% | – |
| Payout ratio | 10.1% | – |
| Years of dividend growth | 5 | – |
| Dividend growth, 5Y average | 46.3% | – |
| Buyback yield | 8.7% (better) | 7.8% |
| Shareholder yield | 9.3% (better) | 7.8% |
| Ownership | ||
| Held by institutions | 64.4% | 101% |
| Held by insiders | 46.0% | 0.97% |
| Insider net buying, 12 months | −$47.5M (better) | −$62.9M |
| Superinvestors holding | 3 (better) | 2 |
| Short interest, % of float | 4.3% | 2.3% |
Go deeper
- HCA stock overview
- HCA income statement
- HCA valuation and score
- THC stock overview
- THC income statement
- THC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.